Leiden, 6 January 2026. BIMINI Biotech has appointed Dr. Helmuth van Es as an Independent Supervisory Board Member.

Dr. van Es brings more than 30 years of experience in biotechnology, drug discovery and development, company building and strategic leadership.

He began his career at Crucell, formerly IntroGene, and later co-founded Galapagos, where he served as Head of Science at the Leiden site. He has since co-founded or held senior leadership and board positions at biotechnology companies including Citryll, Audion Therapeutics, Antabio and Effecta Pharma.

Strengthening BIMINI’s strategic oversight

Dr. van Es has worked across autoimmune disease, infectious disease, oncology and regenerative medicine, with experience spanning early discovery, clinical development and financing.

His appointment adds further drug-development and company-building expertise as BIMINI advances its first-in-class WASp-targeting programmes towards the clinic.

Dr. van Es joins Rob Mayfield, Vasily Kazey and Rouslan Michtchenko in BIMINI’s governance structure.

Commenting on his appointment, Dr. van Es highlighted the therapeutic potential of WASp biology and his ambition to help BIMINI progress its programmes into clinical testing.